A 52-year-old man with long-standing hypertension presents with dyspnea and is found to have left ventricular hypertrophy on echocardiography. Regarding the cellular and molecular basis of cardiac hypertrophy in this condition, all of the following are true EXCEPT:

Explanation

## Cardiac Hypertrophy: Cellular and Molecular Mechanisms ### Key Point: **Hypertrophic cardiomyocytes develop mitochondrial dysfunction and reduced oxidative capacity — this is MALADAPTIVE, not adaptive.** ### Correct Answer Explanation Option 3 is **FALSE** because: 1. **Mitochondrial dysfunction in cardiac hypertrophy is pathologic**, not beneficial 2. Hypertrophic cardiomyocytes show: - Decreased mitochondrial density relative to myofibril volume - Reduced ATP production capacity - Increased reactive oxygen species (ROS) generation - Impaired calcium handling 3. This mitochondrial dysfunction contributes to **diastolic dysfunction** and eventual **heart failure progression** 4. It is NOT an adaptive response that improves efficiency — it is a maladaptive consequence that worsens cardiac function ### Signaling Pathways in Cardiac Hypertrophy ```mermaid flowchart TD A[Increased Mechanical Stretch<br/>Hypertension, Aortic Stenosis]:::outcome --> B[Integrin-FAK-ILK Activation]:::action A --> C[Angiotensin II-AT1R Signaling]:::action B --> D[MAPK Pathway<br/>ERK1/2, p38, JNK]:::action C --> E[Calcineurin-NFAT Pathway<br/>Calcium-dependent]:::action D --> F[Increased Protein Synthesis<br/>mTOR activation]:::action E --> F F --> G[Fetal Gene Re-expression<br/>ANP, β-MHC, α-SMA]:::outcome F --> H[Cardiomyocyte Enlargement]:::outcome H --> I[Mitochondrial Dysfunction<br/>↓ ATP, ↑ ROS]:::urgent I --> J[Diastolic Dysfunction<br/>Heart Failure]:::urgent ``` ### High-Yield: **Mnemonic for cardiac hypertrophy triggers: STRESS** - **S**tretch (mechanical) - **T**ransgenic (genetic factors) - **R**enin-angiotensin system (Ang II) - **E**ndothelin - **S**ympathetic activation (catecholamines) - **S**ystemic hypertension ### Why the Other Options Are Correct | Statement | Mechanism | Evidence | |---|---|---| | **Integrin-FAK-ILK activation** | Mechanotransduction → MAPK/ERK signaling → protein synthesis | Well-established stretch-sensing pathway | | **AT1R-calcineurin-NFAT** | Ang II → IP3/DAG → Ca²⁺ → calcineurin dephosphorylates NFAT → hypertrophic gene expression | Central to pathologic hypertrophy | | **Fetal gene re-expression** | ANP, β-MHC, α-SMA upregulation in hypertrophy | Marker of pathologic remodeling | ### Clinical Pearl: The transition from **compensatory hypertrophy** (early, maintains function) to **pathologic hypertrophy** (late, causes dysfunction) is marked by: - Loss of mitochondrial integrity - Increased oxidative stress - Activation of apoptotic pathways - Development of diastolic dysfunction - Eventually systolic dysfunction and heart failure